Skip to main content

Andrew Berchuck, MD

Andrew Berchuck, MD
James M. Ingram Professor of Gynecologic Oncology
Campus Mail: 25171 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: berch001@mc.duke.edu

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Education and Training

  • M.D., Case Western Reserve University, 1980

Research

Dr Berchuck is interested in the molecular pathogenesis of ovarian and endometrial cancer. 

View Publications

Publications

Teoh, D, Berchuck, A, Alvarez Secord, A, Lee, PS, Lowery, WJ, Sfakianos, GP, Valea, FA, Myers, ER, and Havrilesky, LJ. "Cost comparison of strategies for the management of venous thromboembolic event risk following laparotomy for ovarian cancer." Gynecol Oncol 122, no. 3 (September 2011): 467-472.

Full Text

Skates, SJ, Mai, P, Horick, NK, Piedmonte, M, Drescher, CW, Isaacs, C, Armstrong, DK, Buys, SS, Rodriguez, GC, Horowitz, IR, Berchuck, A, Daly, MB, Domchek, S, Cohn, DE, Van Le, L, Schorge, JO, Newland, W, Davidson, SA, Barnes, M, Brewster, W, Azodi, M, Nerenstone, S, Kauff, ND, Fabian, CJ, Sluss, PM, Nayfield, SG, Kasten, CH, Finkelstein, DM, Greene, MH, and Lu, K. "Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status." Cancer Prev Res (Phila) 4, no. 9 (September 2011): 1401-1408.

Full Text

Barnett, JC, Havrilesky, LJ, Bondurant, AE, Fleming, ND, Lee, PS, Secord, AA, Berchuck, A, and Valea, FA. "Adverse events associated with laparoscopy vs laparotomy in the treatment of endometrial cancer." Am J Obstet Gynecol 205, no. 2 (August 2011): 143.e1-143.e6.

Full Text

Pharoah, P, Antoniou, A, Berchuck, A, Chenevix-Trench, G, Gayther, S, Goode, E, Milne, R, Sellers, T, and Tyrer, J. "Association between KRAS rs61764370 and triple-negative breast cancer--a false positive?." Lancet Oncol 12, no. 8 (August 2011): 723-724. (Letter)

Full Text

Swaminathan, V, Mythreye, K, O'Brien, ET, Berchuck, A, Blobe, GC, and Superfine, R. "Mechanical stiffness grades metastatic potential in patient tumor cells and in cancer cell lines." Cancer Res 71, no. 15 (August 1, 2011): 5075-5080.

Full Text

Permuth-Wey, J, Chen, Z, Tsai, Y-Y, Lin, H-Y, Chen, YA, Barnholtz-Sloan, J, Birrer, MJ, Chanock, SJ, Cramer, DW, Cunningham, JM, Fenstermacher, D, Fridley, BL, Garcia-Closas, M, Gayther, SA, Gentry-Maharaj, A, Gonzalez-Bosquet, J, Iversen, E, Jim, H, McLaughlin, J, Menon, U, Narod, SA, Phelan, CM, Ramus, SJ, Risch, H, Song, H, Sutphen, R, Terry, KL, Tyrer, J, Vierkant, RA, Wentzensen, N, Lancaster, JM, Cheng, JQ, Berchuck, A, Pharoah, PDP, Schildkraut, JM, Goode, EL, and Sellers, TA et al. "MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium." Cancer Epidemiol Biomarkers Prev 20, no. 8 (August 2011): 1793-1797.

Full Text

Pearce, CL, Doherty, JA, Van Den Berg, DJ, Moysich, K, Hsu, C, Cushing-Haugen, KL, Conti, DV, Ramus, SJ, Gentry-Maharaj, A, Menon, U, Gayther, SA, Pharoah, PDP, Song, H, Kjaer, SK, Hogdall, E, Hogdall, C, Whittemore, AS, McGuire, V, Sieh, W, Gronwald, J, Medrek, K, Jakubowska, A, Lubinski, J, Chenevix-Trench, G, AOCS/ACS Study Group, , Beesley, J, Webb, PM, Berchuck, A, Schildkraut, JM, Iversen, ES, Moorman, PG, Edlund, CK, Stram, DO, Pike, MC, Ness, RB, Rossing, MA, and Wu, AH. "Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk." Hum Mol Genet 20, no. 11 (June 1, 2011): 2263-2272.

Full Text

Maxwell, GL, Hood, BL, Day, R, Chandran, U, Kirchner, D, Kolli, VSK, Bateman, NW, Allard, J, Miller, C, Sun, M, Flint, MS, Zahn, C, Oliver, J, Banerjee, S, Litzi, T, Parwani, A, Sandburg, G, Rose, S, Becich, MJ, Berchuck, A, Kohn, E, Risinger, JI, and Conrads, TP. "Proteomic analysis of stage I endometrial cancer tissue: identification of proteins associated with oxidative processes and inflammation." Gynecol Oncol 121, no. 3 (June 1, 2011): 586-594.

Full Text

Pharoah, PDP, Palmieri, RT, Ramus, SJ, Gayther, SA, Andrulis, IL, Anton-Culver, H, Antonenkova, N, Antoniou, AC, Goldgar, D, BCFR Investigators, , Beattie, MS, Beckmann, MW, Birrer, MJ, Bogdanova, N, Bolton, KL, Brewster, W, Brooks-Wilson, A, Brown, R, Butzow, R, Caldes, T, Caligo, MA, Campbell, I, Chang-Claude, J, Chen, YA, Cook, LS, Couch, FJ, Cramer, DW, Cunningham, JM, Despierre, E, Doherty, JA, Dörk, T, Dürst, M, Eccles, DM, Ekici, AB, Easton, D, EMBRACE Investigators, , and Fasching, PA et al. "The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing." Clin Cancer Res 17, no. 11 (June 1, 2011): 3742-3750.

Full Text

Berchuck, A, Pharoah, P, Ramus, S, Gayther, S, Palmieri, R, Pearce, C, Couch, F, Antonio, A, Goode, E, Schildkraut, J, Chenevix-Trench, G, Sellers, T, Risch, H, Modifiers, CI, and Consortium, OCA. "Association of KRAS SNP rs61764370 with risk of invasive epithelial ovarian cancer: Implications for clinical testing." GYNECOLOGIC ONCOLOGY 121, no. 2 (May 1, 2011): S2-S3.

Full Text

Pages